Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

INTERVENTIONALInicio: 22 de jul de 2025ID: NCT07064759

ReclutandoFase 2ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.

INTERVENTIONALInicio: 9 de dic de 2024ID: NCT06588686

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

INTERVENTIONALInicio: 16 de nov de 2023ID: NCT05920356

ReclutandoFase 3ClinicalTrials.gov

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

INTERVENTIONALInicio: 30 de abr de 2025ID: NCT06948422

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

INTERVENTIONALInicio: 19 de may de 2025ID: NCT06830798

ReclutandoFase 2ClinicalTrials.gov

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

INTERVENTIONALInicio: 16 de jul de 2025ID: NCT07033494

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

INTERVENTIONALInicio: 18 de jul de 2025ID: NCT06929273

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

INTERVENTIONALInicio: 6 de sept de 2022ID: NCT05334368

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy

INTERVENTIONALInicio: 12 de jul de 2024ID: NCT06290128

ReclutandoFase 3ClinicalTrials.gov

Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine

INTERVENTIONALInicio: 1 de dic de 2021ID: NCT05164172

ReclutandoFase 3ClinicalTrials.gov

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

INTERVENTIONALInicio: 6 de ene de 2025ID: NCT06760637

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

INTERVENTIONALInicio: 6 de may de 2025ID: NCT06747351

ReclutandoFase 3ClinicalTrials.gov

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

INTERVENTIONALInicio: 2 de jul de 2025ID: NCT07052903

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

INTERVENTIONALInicio: 19 de ene de 2026ID: NCT07216703

ReclutandoFase 3ClinicalTrials.gov

A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

INTERVENTIONALInicio: 17 de sept de 2025ID: NCT07190222

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.

INTERVENTIONALInicio: 10 de dic de 2024ID: NCT06637631

ReclutandoFase 3ClinicalTrials.gov

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

INTERVENTIONALInicio: 9 de feb de 2026ID: NCT07353931

ReclutandoFase 3ClinicalTrials.gov

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

INTERVENTIONALInicio: 19 de jul de 2023ID: NCT05843643

ReclutandoFase 1ClinicalTrials.gov

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease

INTERVENTIONALInicio: 11 de jun de 2022ID: NCT05003947

ReclutandoClinicalTrials.gov

Prospective Multicenter Field Study for Rapid Diagnostic Tests Evaluation for Timely Detection of Chronic Chagas Disease in Public Health Sites in Argentina.

OBSERVATIONALInicio: 29 de ago de 2025ID: NCT07304349